Print

Daiichi Sankyo, Inc. (D4S.F) Buys Shanghai Xinshengyuan Pharma  
4/23/2012 12:03:53 PM

April 20, 2012 --Daiichi Sankyo's China subsidiary has gained control of Shanghai Xinshengyuan Pharmaceutical Group Medicine & Chemical Reagents Sales Co., a company that imports Ranbaxy's generic drug portfolio into China. Daiichi and Ranbaxy are already partners. In 2008, Daiichi Sankyo paid $4.6 billion for a controlling interest in Ranbaxy, adding generic drugs to Daiichi Sankyo's portfolio of innovative drugs. By buying Xinshengyuan, Daiichi gains control of its partner's products in China. More details....

Stock Symbols: (TO: 4658) (BSE: 500359)


//-->